Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.64 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122350 | 1.00 | CTSS (0.64) | CTSSCTSKPSENENCA2KDM4E | |
| SCHEMBL18766187 | 0.93 | CTSS (0.68) | CTSSCTSKPSENENCA2KDM4E | |
| SCHEMBL11405307 | 0.93 | CTSS (0.68) | CTSSCTSKPSENENCA2KDM4E | |
| SCHEMBL11570829 | 0.91 | CTSS (0.56) | CTSSCTSKPSENENCA2ALDH1A1 | |
| SCHEMBL11570820 | 0.91 | CTSS (0.56) | CTSSCTSKPSENENCA2ALDH1A1 | |
| SCHEMBL22068618 | 0.90 | CTSS (0.65) | CTSSCTSKPSENENCA2 | |
| SCHEMBL22068619 | 0.90 | CTSS (0.65) | CTSSCTSKPSENENCA2 | |
| SCHEMBL31139338 | 0.89 | CTSS (0.64) | CTSSCTSKPSENENCA2ALDH1A1 | |
| SCHEMBL31139352 | 0.89 | CTSS (0.64) | CTSSCTSKPSENENCA2ALDH1A1 | |
| SCHEMBL8492292 | 0.87 | CTSS (0.61) | CTSSCTSKPSENENCA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | DLST, VIP, HAMP | CTSS 642/4885CTSK 571/4885PSENEN 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.